LNC Therapeutics Receives FDA Investigational New Drug Approval to Initiate a Phase 1 Clinical Trial on Xla1 for the Treatment of Obesity and Metabolic Diseases
9 September 2020

LNC Therapeutics Receives FDA Investigational New Drug Approval to Initiate a Phase 1 Clinical Trial on Xla1 for the Treatment of Obesity and Metabolic Diseases

LNC Therapeutics, a French biotech company harnessing the properties of keystone single-strain bacteria to develop ground-breaking microbiome-based drugs, today announced that...